Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Rises By 269.2%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 62,400 shares, a growth of 269.2% from the September 30th total of 16,900 shares. Currently, 3.4% of the shares of the company are sold short. Based on an average trading volume of 804,800 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 804,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.4% of the shares of the company are sold short.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Sachetta LLC boosted its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,259 shares of the company’s stock after purchasing an additional 4,593 shares during the period. Sachetta LLC owned about 0.99% of Xenetic Biosciences worth $60,000 at the end of the most recent reporting period. 15.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Xenetic Biosciences Stock Down 4.5%

Shares of NASDAQ XBIO opened at $3.58 on Wednesday. Xenetic Biosciences has a 52 week low of $2.20 and a 52 week high of $13.93. The business has a 50-day simple moving average of $3.72 and a two-hundred day simple moving average of $3.34. The company has a market cap of $5.51 million, a P/E ratio of -1.79 and a beta of 2.42.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.19. Xenetic Biosciences had a negative return on equity of 54.56% and a negative net margin of 126.08%.The firm had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.48 million. Equities research analysts anticipate that Xenetic Biosciences will post -1.01 EPS for the current year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.